Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, despite the challenging events swirling about, because the usual routine of deadlines, Zoom and Skype calls, and growing to-do lists has, of course, returned. You knew this would happen, yes? After all, the world keeps spinning. So time to get cracking. Here are a few items of interest to help you get started. We hope your day is tolerable and even productive. And as always, do keep in touch. …

In a stunning declaration of authority, Health and Human Services Secretary Alex Azar barred the nation’s health agencies, including the Food and Drug Administration, from signing any new rules regarding the nation’s foods, medicines, medical devices, and other products, including vaccines, The New York Times reports. It remains unclear if or how the move would change the vetting and approval process for Covid-19 vaccines, three of which are in advanced clinical trials in the U.S.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • May one observe that, if the NY Times reporting is correct, Mr Meadows was attempting to take the concept of “buying votes / voters” (albeit with other peoples money) to a new level? On second thought, was he attempting to facilitate bribery?

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy